Literature DB >> 33706754

Quality of diabetes care in patients with schizophrenia: a case-control study in Qatar.

Mustafa Abdul Karim1, Nadeen Al-Baz1, Sami Ouanes1, Ali Khalil1, Ahmed H Assar2, Abdulkarim Alsiddiqi2, Zeinab Dabbous3, Mahmoud Zirie3, Peter Woodruff1,2, Rayaz A Malik2, Peter M Haddad4,5,6.   

Abstract

BACKGROUND: Patients with schizophrenia are at least twice as likely to develop diabetes mellitus compared to the general population. This is of significance in Qatar given the high prevalence of obesity and diabetes. Furthermore, the lifespan of people with schizophrenia is shortened by approximately 15 years, partly due to long-term microvascular and macrovascular complications. High quality diabetes care can significantly reduce morbidity and mortality. We assessed the level of diabetes care delivered to patients in Qatar with schizophrenia and diabetes compared to those with diabetes alone.
METHODS: We performed a retrospective chart review of patients with diabetes mellitus with (n = 73) and without (n = 73) schizophrenia. Demographic information and electronic medical records were reviewed to determine adherence to American Diabetes Association standards of diabetes care in the last 6 and 12 months. Optimal diabetes care was defined as having completed glycated hemoglobin (HbA1c), lipid profile and retinal examination within 12 months.
RESULTS: Optimal diabetes care was significantly lower in patients with schizophrenia and diabetes compared to diabetes alone [26.0% (n = 19/73) vs 52.1% (n = 38/73), p = 0.002]. Patients with diabetes and schizophrenia were also significantly less likely to have had body mass index recorded within 6 months (p = 0.008) and HbA1c (p = 0.006), lipid profile (p = 0.015), estimated glomerular filtration rate (eGFR) (p = 0.001) and order for retinal examination (p = 0.004) over 12 months. After adjusting for multiple comparisons, only assessment of eGFR (p = 0.01) and order for retinal examination (p = 0.04) remained significant.
CONCLUSION: Patients in Qatar with schizophrenia and diabetes, receive sub-optimal diabetes care compared to those with diabetes alone.

Entities:  

Keywords:  Diabetes care; Diabetes mellitus; Schizophrenia

Year:  2021        PMID: 33706754      PMCID: PMC7953779          DOI: 10.1186/s12888-021-03121-5

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


  26 in total

Review 1.  The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness.

Authors:  Joseph Firth; Najma Siddiqi; Ai Koyanagi; Dan Siskind; Simon Rosenbaum; Cherrie Galletly; Stephanie Allan; Constanza Caneo; Rebekah Carney; Andre F Carvalho; Mary Lou Chatterton; Christoph U Correll; Jackie Curtis; Fiona Gaughran; Adrian Heald; Erin Hoare; Sarah E Jackson; Steve Kisely; Karina Lovell; Mario Maj; Patrick D McGorry; Cathrine Mihalopoulos; Hannah Myles; Brian O'Donoghue; Toby Pillinger; Jerome Sarris; Felipe B Schuch; David Shiers; Lee Smith; Marco Solmi; Shuichi Suetani; Johanna Taylor; Scott B Teasdale; Graham Thornicroft; John Torous; Tim Usherwood; Davy Vancampfort; Nicola Veronese; Philip B Ward; Alison R Yung; Eoin Killackey; Brendon Stubbs
Journal:  Lancet Psychiatry       Date:  2019-07-16       Impact factor: 27.083

2.  Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.

Authors:  Jimmi Nielsen; Søren Skadhede; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-06-02       Impact factor: 7.853

Review 3.  The Complex Inter-Relationship Between Diabetes and Schizophrenia.

Authors:  Robert P Hoffman
Journal:  Curr Diabetes Rev       Date:  2017

4.  Quality and Predictors of Diabetes Care Among Patients With Schizophrenia: A Danish Nationwide Study.

Authors:  Mette Jørgensen; Jan Mainz; Fabrizio Carinci; Reimar W Thomsen; Søren Paaske Johnsen
Journal:  Psychiatr Serv       Date:  2017-10-16       Impact factor: 3.084

5.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

6.  Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis.

Authors:  Carsten Hjorthøj; Anne Emilie Stürup; John J McGrath; Merete Nordentoft
Journal:  Lancet Psychiatry       Date:  2017-02-22       Impact factor: 27.083

7.  Management of mental health problems by general practitioners in Quebec.

Authors:  Marie-Josée Fleury; Lambert Farand; Denise Aubé; Armelle Imboua
Journal:  Can Fam Physician       Date:  2012-12       Impact factor: 3.275

Review 8.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

9.  Schizophrenia and attendance in primary healthcare: a population-based matched cohort study.

Authors:  H C B Nørgaard; H Schou Pedersen; M Fenger-Grøn; M Vestergaard; M Nordentoft; T M Laursen; O Mors
Journal:  Scand J Prim Health Care       Date:  2019-07-12       Impact factor: 2.581

10.  The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study.

Authors:  Samer Hammoudeh; Suhaila Ghuloum; Ziyad Mahfoud; Arij Yehya; Abdulmoneim Abdulhakam; Azza Al-Mujalli; Mahmoud Al-Zirie; Mohamed Osman Abdel Rahman; Angela Godwin; Noura Younes; Yahya Hani; Dennis Mook-Kanamori; Marjonneke Mook-Kanamori; Reem El Sherbiny; Hassen Al-Amin
Journal:  BMC Psychiatry       Date:  2018-03-27       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.